Commitment to Fight COVID-19

Commitment to Fight COVID-19

As of May 30, 2022

[Wastewater-based Epidemiology Surveillance Service]

[Wastewater-based Epidemiology Surveillance Service]

By measuring the traces of the virus in wastewater, it is possible to assess, in an unbiased manner, the prevalence of SARS-CoV-2 infections in a community, including asymptomatic individuals who are not tested.

medicines and beyond, creating the next generation of healthcare
TVCM "Medicines and beyond"
our medium-term business plan

［Mid-term Business plan］

STS2030

~Shionogi Transformation Strategy 2030~

Outline / CEO interview movie

Drive Innovation

［Innovation］

Drive Innovation

Create innovations beyond the borders of medical / Pharmaceutical fields, unbound from existing concepts, showing every consideration for social issues

Sustainability

［Sustainability］

Grow sustainably as a drug discovery based pharmaceutical company contributing to a more vigorous society through improved healthcare

News

Sep.28, 2022 Release
Shionogi Announces Achievement of the Primary Endpoint for Ensitrelvir Fumaric Acid (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia
Sep.22, 2022 Release
Shionogi Announces Corporate Reorganization and Personnel Reassignment
Sep.21, 2022 Release
Shionogi Healthcare, Shionogi, and Pixie Dust Technologies Enter a Business Partnership Agreement to Launch Business Involving Brain Activation through Sound Stimulation
- Aiming to Start Selling Products to Ordinary Households in Spring 2023 -
Sep.16, 2022 Release
Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Ildong for Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, for South Korea
Sep.07, 2022 Release
Notice regarding the Beginning of Solar Power Generation at a Health Facility in Kilifi County, Kenya under the “Mother to Mother SHIONOGI Project”
News

Commitment to Fight COVID-19

Shionogi's effort to fight with COVID-19

Beware of Solicitations, “Phishing” e-mails, and SNS that Fraudulently Use the Name of SHIONOGI

Site Search

Brand Statement

Building innovation platforms to shape the future of healthcare.

SHIONOGI is transforming our business model from a "drug-discovery-oriented pharmaceutical company" to a "healthcare provider" to pursue the health that people truly wish for and deliver new value to society.

more

About Shionogi

We are fully committed to achieving the goals of STS2030 and strive to realizing "SHIONOGI Group heritage" globally.

Sustainability

Shionogi's susutainability programs which toward to become a company that will be needed by stakeholders now and in the future.

Innovation

Shionogi's Innovation always comes from the passion to provide new value which meet the needs of society and customers, in the healthcare field.

Investors

Based on disclosure policy, Shionogi disclose information fairly, timely, appropriately and continuously to all stakeholders.